ECSP15010617A - Formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa campo de la invención - Google Patents
Formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa campo de la invenciónInfo
- Publication number
- ECSP15010617A ECSP15010617A ECIEPI201510617A ECPI201510617A ECSP15010617A EC SP15010617 A ECSP15010617 A EC SP15010617A EC IEPI201510617 A ECIEPI201510617 A EC IEPI201510617A EC PI201510617 A ECPI201510617 A EC PI201510617A EC SP15010617 A ECSP15010617 A EC SP15010617A
- Authority
- EC
- Ecuador
- Prior art keywords
- hmg
- formulation
- coa reductase
- reductase inhibitor
- irbesartan
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 4
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 title abstract 4
- 239000002947 C09CA04 - Irbesartan Substances 0.000 title abstract 3
- 239000002775 capsule Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 3
- 229960002198 irbesartan Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000002131 composite material Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 239000007963 capsule composition Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se divulgan una formulación de una cápsula farmacéutica compuesta que comprende 1) una unidad de irbesartan independiente que comprende irbesartan o una de sus sales aceptables desde el punto de vista farmacéutico; y 2) una unidad independiente de inhibidor de la HMG-CoA reductasa que comprende un inhibidor de la HMG-CoA reductasa o una de sus sales aceptables desde el punto de vista farmacéutico, y un aditivo alcalino, en donde dichas unidades independientes se separan unas de otras dentro de una cápsula, y un método para preparar la misma. Diseñada para prevenir una interacción entre irbesartan y el inhibidor de la HMG-CoA reductasa, la formulación de una cápsula farmacéutica compuesta es mejorada en estabilidad y velocidad de disolución, y de este modo muestra gran biodisponibilidad. Además, se espera que la formulación garantice un alto cumplimiento del medicamento debido a su pequeño tamaño, y por lo tanto puede aplicarse al tratamiento de la hipertensión e hipercolesterolemia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120096036A KR20140030505A (ko) | 2012-08-31 | 2012-08-31 | 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP15010617A true ECSP15010617A (es) | 2015-12-31 |
Family
ID=50183919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201510617A ECSP15010617A (es) | 2012-08-31 | 2015-03-20 | Formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa campo de la invención |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20150231085A1 (es) |
| EP (1) | EP2890371A4 (es) |
| JP (1) | JP2015526509A (es) |
| KR (1) | KR20140030505A (es) |
| CN (1) | CN104602678A (es) |
| AR (1) | AR092385A1 (es) |
| AU (1) | AU2013309688A1 (es) |
| BR (1) | BR112015004091A2 (es) |
| CA (1) | CA2882738A1 (es) |
| CL (1) | CL2015000363A1 (es) |
| CO (1) | CO7350622A2 (es) |
| CR (1) | CR20150124A (es) |
| DO (1) | DOP2015000042A (es) |
| EA (1) | EA201590474A1 (es) |
| EC (1) | ECSP15010617A (es) |
| IL (1) | IL237425A0 (es) |
| IN (1) | IN2015DN01738A (es) |
| MA (1) | MA37953A1 (es) |
| MX (1) | MX2015002591A (es) |
| NI (1) | NI201500028A (es) |
| PE (1) | PE20150402A1 (es) |
| PH (1) | PH12015500395A1 (es) |
| RU (1) | RU2015111523A (es) |
| SG (1) | SG11201500580QA (es) |
| TW (1) | TW201414511A (es) |
| UY (1) | UY35000A (es) |
| WO (1) | WO2014035190A1 (es) |
| ZA (1) | ZA201502157B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101771766B1 (ko) * | 2013-12-30 | 2017-08-28 | 알보젠코리아 주식회사 | 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제 |
| EP3184103A1 (en) * | 2015-12-21 | 2017-06-28 | Hexal AG | Pharmaceutical composition comprising atorvastatin or a salt thereof |
| AU2018307910B2 (en) * | 2017-07-25 | 2024-07-25 | Daiichi Sankyo Company, Limited | Formulations of a compound modulating kinases |
| CN110237070A (zh) * | 2019-05-10 | 2019-09-17 | 辽宁大学 | 厄贝沙坦在制备降血脂药物中的应用 |
| CN116669715A (zh) * | 2020-11-18 | 2023-08-29 | Fb-Hrs有限责任公司 | 含有多非利特和美西律的组合物及其应用 |
| CN113476423A (zh) * | 2021-07-05 | 2021-10-08 | 海南通用三洋药业有限公司 | 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| PE20030324A1 (es) * | 2001-07-31 | 2003-04-03 | Warner Lambert Co | Composiciones farmaceuticas de amlodipina y atorvastatina |
| DE602005025755D1 (de) * | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
| WO2008010008A2 (en) * | 2006-07-17 | 2008-01-24 | Wockhardt Limited | Cardiovascular combinations using rennin-angiotensin inhibitors |
| US20110212175A1 (en) * | 2006-10-30 | 2011-09-01 | Hanall Biopharma Co., Ltd. | Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor |
| DK2273985T3 (en) * | 2008-03-28 | 2016-04-25 | Ferrer Int | Capsule for the prevention of cardiovascular diseases |
| KR20090114323A (ko) * | 2008-04-29 | 2009-11-03 | 한올제약주식회사 | 약제학적 제제 |
| EP2424509A4 (en) * | 2009-04-30 | 2012-11-07 | Reddys Lab Ltd Dr | MEDICINAL COMBINATION FORMULATIONS WITH DETERMINED DOSAGE |
| KR101248804B1 (ko) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
| US9056134B2 (en) * | 2010-07-21 | 2015-06-16 | Nucitec S.A. De C.V. | Single daily dosage form for prevention and treatment of metabolic syndrome |
-
2012
- 2012-08-31 KR KR1020120096036A patent/KR20140030505A/ko not_active Ceased
-
2013
- 2013-08-29 AR ARP130103082A patent/AR092385A1/es unknown
- 2013-08-30 EP EP13834178.9A patent/EP2890371A4/en not_active Withdrawn
- 2013-08-30 EA EA201590474A patent/EA201590474A1/ru unknown
- 2013-08-30 CA CA2882738A patent/CA2882738A1/en not_active Abandoned
- 2013-08-30 UY UY0001035000A patent/UY35000A/es not_active Application Discontinuation
- 2013-08-30 TW TW102131242A patent/TW201414511A/zh unknown
- 2013-08-30 AU AU2013309688A patent/AU2013309688A1/en not_active Abandoned
- 2013-08-30 SG SG11201500580QA patent/SG11201500580QA/en unknown
- 2013-08-30 WO PCT/KR2013/007841 patent/WO2014035190A1/en not_active Ceased
- 2013-08-30 US US14/420,953 patent/US20150231085A1/en not_active Abandoned
- 2013-08-30 IN IN1738DEN2015 patent/IN2015DN01738A/en unknown
- 2013-08-30 CN CN201380045368.3A patent/CN104602678A/zh active Pending
- 2013-08-30 RU RU2015111523A patent/RU2015111523A/ru not_active Application Discontinuation
- 2013-08-30 BR BR112015004091A patent/BR112015004091A2/pt not_active IP Right Cessation
- 2013-08-30 MX MX2015002591A patent/MX2015002591A/es unknown
- 2013-08-30 JP JP2015529684A patent/JP2015526509A/ja active Pending
- 2013-08-30 PE PE2015000255A patent/PE20150402A1/es not_active Application Discontinuation
-
2015
- 2015-02-16 CL CL2015000363A patent/CL2015000363A1/es unknown
- 2015-02-24 PH PH12015500395A patent/PH12015500395A1/en unknown
- 2015-02-25 IL IL237425A patent/IL237425A0/en unknown
- 2015-02-26 DO DO2015000042A patent/DOP2015000042A/es unknown
- 2015-02-27 NI NI201500028A patent/NI201500028A/es unknown
- 2015-03-11 CR CR20150124A patent/CR20150124A/es unknown
- 2015-03-13 CO CO15058341A patent/CO7350622A2/es unknown
- 2015-03-20 EC ECIEPI201510617A patent/ECSP15010617A/es unknown
- 2015-03-27 MA MA37953A patent/MA37953A1/fr unknown
- 2015-03-30 ZA ZA2015/02157A patent/ZA201502157B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2890371A4 (en) | 2016-04-06 |
| MA37953A1 (fr) | 2017-01-31 |
| JP2015526509A (ja) | 2015-09-10 |
| ZA201502157B (en) | 2016-10-26 |
| CA2882738A1 (en) | 2014-03-06 |
| DOP2015000042A (es) | 2015-04-30 |
| IN2015DN01738A (es) | 2015-05-29 |
| EA201590474A1 (ru) | 2015-06-30 |
| BR112015004091A2 (pt) | 2017-07-04 |
| US20150231085A1 (en) | 2015-08-20 |
| CO7350622A2 (es) | 2015-08-10 |
| TW201414511A (zh) | 2014-04-16 |
| PH12015500395A1 (en) | 2015-04-27 |
| AR092385A1 (es) | 2015-04-22 |
| WO2014035190A1 (en) | 2014-03-06 |
| IL237425A0 (en) | 2015-04-30 |
| KR20140030505A (ko) | 2014-03-12 |
| CR20150124A (es) | 2015-04-24 |
| PE20150402A1 (es) | 2015-04-13 |
| SG11201500580QA (en) | 2015-02-27 |
| CL2015000363A1 (es) | 2015-06-05 |
| CN104602678A (zh) | 2015-05-06 |
| UY35000A (es) | 2014-03-31 |
| NI201500028A (es) | 2017-01-04 |
| AU2013309688A1 (en) | 2015-02-26 |
| RU2015111523A (ru) | 2016-10-20 |
| EP2890371A1 (en) | 2015-07-08 |
| MX2015002591A (es) | 2015-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP15010617A (es) | Formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa campo de la invención | |
| MX2016005394A (es) | Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4. | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| TN2015000505A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| MX2016006667A (es) | Derivados de pirrolo-pirrolona y su uso como inhibidores. | |
| MX2016001480A (es) | Formulacion de inhibidores de syk. | |
| CR20120545A (es) | Formulación farmacéutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan | |
| EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
| CR20160438A (es) | Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación | |
| MX2017012295A (es) | Derivados formilados n-heterociclicos como inhibidores de fgfr4. | |
| SV2016005313A (es) | Derivados de carboxamida | |
| AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
| EA201591175A1 (ru) | Трициклические соединения в качестве ингибиторов cftr | |
| MX2016014946A (es) | Derivados de carboxamida. | |
| TR201310724A2 (tr) | Linagliptinin farmasotik formulasyonları. | |
| ECSP15010600A (es) | Formulación de comprimidos compuestos de dos fases que comprende atorvastatina, irbesartan y carbonato de magnesio | |
| EA201200799A1 (ru) | Гепатопротекторное средство | |
| CU20160170A7 (es) | Derivados de carboxamida | |
| TH157686A (th) | ตัวยับยั้ง cdc7 | |
| UA110834C2 (uk) | Сполука-інгібітор сигнального шляху notch |